| Not Yet Recruiting | A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1 NCT02944955 | BioLite, Inc. | Phase 2 |
| Recruiting | Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (L NCT07008820 | Bristol-Myers Squibb | — |
| Recruiting | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With NCT06548230 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics NCT05534620 | medac GmbH | Phase 1 |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Enrolling By Invitation | Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome NCT05674539 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Completed | A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects NCT06294275 | Longbio Pharma | Phase 1 |
| Completed | Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Ques NCT05817331 | Otsuka Australia Pharmaceutical Pty Ltd | — |
| Terminated | STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS NCT04878432 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN NCT04639024 | Gwynn Long, M.D. | Phase 2 |
| Recruiting | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT05143996 | Cullinan Therapeutics Inc. | Phase 1 |
| Suspended | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) NCT05168904 | Cyclacel Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azaci NCT04912063 | AbbVie | Phase 1 |
| Terminated | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participan NCT04812548 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations NCT04603001 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome NCT04608110 | Taiho Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity I NCT04401748 | AbbVie | Phase 3 |
| Completed | TPO-Mimetic Use in Children for Hematopoietic Failure NCT04478227 | Anjali Sharathkumar | EARLY_Phase 1 |
| Unknown | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transpla NCT04429191 | Jasper Therapeutics, Inc. | Phase 1 |
| Unknown | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT NCT04284228 | NexImmune Inc. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies NCT06550713 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Withdrawn | A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome NCT03486353 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 2 |
| Terminated | CPX-351 Therapy for MDS After Hypomethylating Agent Failure NCT03957876 | Case Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MD NCT03613532 | Jacqueline Garcia, MD | Phase 1 |
| Completed | A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes NCT03516591 | Amphivena Therapeutics, Inc. | Phase 1 |
| Terminated | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia NCT03600909 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study NCT03335943 | Chinese Society of Hematology | Phase 4 |
| Recruiting | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM NCT03173937 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT NCT02989844 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic NCT02979366 | Institut de Recherches Internationales Servier | Phase 1 |
| Terminated | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome NCT02749708 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M NCT02730299 | Gamida Cell ltd | Phase 3 |
| Completed | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide NCT02793544 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Unknown | Myelodysplasic Syndromes and Risk Factors for Infection NCT02905552 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haplo NCT02790515 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY NCT02992860 | GWT-TUD GmbH | Phase 2 |
| Terminated | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plu NCT02648932 | University of Chicago | Phase 2 |
| Withdrawn | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrom NCT01520805 | Cornerstone Pharmaceuticals | Phase 2 |
| Completed | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS NCT02626715 | Randy Windreich | Phase 2 |
| Terminated | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients NCT02433483 | St. Jude Children's Research Hospital | Phase 2 |
| Withdrawn | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS NCT02204020 | University of Pittsburgh | Phase 2 |
| Withdrawn | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome f NCT02269579 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysp NCT02920541 | Institut de Recherches Internationales Servier | Phase 1 |
| Unknown | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer NCT02240537 | Benovus Bio, Inc. | Phase 1 |
| Terminated | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic NCT02212561 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re NCT02200380 | Celldex Therapeutics | Phase 2 |
| Completed | An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Fo NCT02238925 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Darbepoetin Alfa MDS Companion Protocol NCT02175277 | Amgen | Phase 3 |
| Terminated | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL NCT02147873 | TetraLogic Pharmaceuticals | Phase 2 |
| Recruiting | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy NCT02143830 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Unknown | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transpla NCT01983761 | Targazyme, Inc. | Phase 1 / Phase 2 |
| Completed | Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT NCT01772953 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) NCT01842646 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients NCT01929408 | Fred Hutchinson Cancer Center | — |
| Active Not Recruiting | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant NCT02061800 | Diane George | Phase 1 / Phase 2 |
| Completed | Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment NCT02099266 | University of Kansas Medical Center | N/A |
| Completed | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NCT01816230 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | AML-MDS Novel Prognostic Tests Clinical Study NCT01685619 | Nova Scotia Health Authority | — |
| Completed | Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplasti NCT01599325 | Celgene | Phase 2 |
| Completed | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568 | Polyphor Ltd. | Phase 1 / Phase 2 |
| Completed | Improving Blood Stem Cell Collection and Transplant Procedures NCT01517035 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Unknown | Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS NCT02124174 | Patrick Stiff | Phase 2 |
| Terminated | Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome NCT01422486 | Telik | Phase 2 |
| Terminated | Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome NCT01459159 | Telik | Phase 2 |
| Completed | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cycloph NCT01342289 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia NCT01286038 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia NCT01362036 | Tarix Pharmaceuticals | Phase 1 |
| Completed | Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low NCT01338337 | Asociación Andaluza de Hematología y Hemoterapia | Phase 2 |
| Completed | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie NCT01221857 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Suspended | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) NCT01211691 | Humanigen, Inc. | Phase 1 / Phase 2 |
| Terminated | LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk NCT01034657 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients Wi NCT00977132 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Completed | Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopen NCT01224496 | Singapore General Hospital | Phase 1 / Phase 2 |
| Terminated | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764 | Everett Meyer | Phase 1 / Phase 2 |
| Completed | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer W NCT00796068 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Tran NCT00749372 | Weill Medical College of Cornell University | N/A |
| Terminated | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acut NCT00666497 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) NCT00700206 | Telik | Phase 2 |
| Completed | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acu NCT00656617 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome Wi NCT00655395 | Viron Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) NCT00502112 | Seagen Inc. | Phase 1 |
| Completed | Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood NCT00923910 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Mali NCT00566696 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Sy NCT00542828 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Safety of ON 01910.Na in Patients With Myelodysplasia NCT00533416 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia NCT00664677 | Erimos Pharmaceuticals | Phase 1 |
| Completed | Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a NCT00673114 | Joanne Kurtzberg, MD | Phase 1 / Phase 2 |
| Completed | Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers NCT00488592 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation NCT00672152 | Michael Morse, MD | Phase 1 |
| Completed | Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Co NCT00682799 | Charlotte Niemeyer, MD | — |
| Completed | 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS NCT00339196 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) NCT00280631 | Telik | Phase 1 / Phase 2 |
| Completed | Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome NCT00270452 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Unknown | MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank NCT02537990 | Sunnybrook Health Sciences Centre | — |
| Enrolling By Invitation | Biology Studies of Hematologic Cancers NCT00923442 | National Cancer Institute (NCI) | — |
| Terminated | Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) NCT00225992 | Oncology Specialties, Alabama | Phase 2 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00186823 | St. Jude Children's Research Hospital | Phase 3 |